The diagnosis-specific graded prognostic assessment scale (ds-GPA) for patients with melanoma brain metastasis (BM) utilizes only 2 key prognostic variables: Karnofsky performance status and the number of intracranial metastases. We wished to determine whether inclusion of cumulative intracranial tumor volume (CITV) into the ds-GPA model for melanoma augmented its prognostic value. OBJECTIVE: To determine whether or not CITV augments the ds-GPA prognostic scale for melanoma.
M
edical and surgical treatment decisions for patients suffering from brain metastasis (BM) are guided by survival expectations. 1 Prognostic indices for cancer patients suffering from BM are particularly important in this regard. [2] [3] [4] While initial efforts to develop a prognostic index for BM ABBREVIATIONS: AIC, Akaike information criterion; BM, brain metastasis; CITV, cumulative intracranial tumor volume; ds-GPA, diagnosis-specific graded prognostic assessment; IDI, integrated discrimination improvement; KPS, Karnofsky performance status; MRI, magnetic resonance imaging; NRI, net reclassification index; SRS, stereotactic radiosurgery patients aggregated many primary tumors into a single analytic model, 2, 5, 6 subsequent studies have suggested that distinct prognostic scales be used for tumors of differing primary pathology. [7] [8] [9] The impetus for the creation of the diagnosis-specific graded prognostic assessment scale (ds-GPA) was the observation that certain clinical variables were only effective in predicting survival in certain diseases. 7 For instance, the ds-GPA survival prognostication for lung cancer patients involves 4 clinical variables (age, Karnofsky performance status [KPS] , presence of extracranial metastasis, and number of BMs) while survival prognostication for melanoma and renal cell carcinoma patients with BM requires only 2 clinical variables (KPS and number of BMs). Notably, ds-GPA has been validated subsequently in independent patient cohorts. 10 Previous work done by our group and others has suggested the importance of an additional prognostic factor for BM patients that was not previously examined in the ds-GPA: cumulative intracranial tumor volume (CITV). 11, 12 CITV is defined as the sum volume of all intracranial metastases. 10, 13 Importantly, CITV was shown to correlate poorly with the number of BM in lung cancer patients, suggesting significant heterogeneity in the volume of the BM. 12 Moreover, CITV remains a potent factor for survival prognostication after accounting for all ds-GPA variables, including age, KPS, number of metastases, and primary tumor histology. 12 The incorporation of CITV into the ds-GPA model for lung cancer augmented its prognostic value in independent patient cohorts. 12 However, whether incorporation of CITV into melanoma ds-GPA affords similar improvements remains unclear. Here, we tested the impact of CITV on the prognostic value of melanoma ds-GPA.
METHODS

Study Cohorts
All data collection was performed under a retrospective review approved by the Institutional Review Board. In order to study melanoma BM patients, we generated a cohort of patients from combined data sets of patients treated at separate academic institutions between 1995 and 2009. This cohort consisted of 344 melanoma BM patients; details of members of this cohort have been previously published.
14,15 A similarly collected data set of 201 patients was used as a validation set. All patients were known to have metastatic intracranial disease (ie, a primary tumor confirmed outside of the central nervous system and a distant metastasis inside the central nervous system), and underwent stereotactic radiosurgery (SRS) for their intracranial disease without craniotomy. Patients who underwent surgical resection were excluded from our analysis. Other than the geographic location of approximately one-third (36%) of the patients, the study parameters did not differ significantly from the original ds-GPA. 8 All available data were included in the analyses performed. The treatment practices carried out by each of the treating physicians were consistent with Radiation Therapy Oncology Group guidelines, although treatments were individualized to each patient's general and oncological condition. 16 Whole-brain radiotherapy was restricted to those patients undergoing palliative care or with miliary metastases, who could not reliably follow up with serial magnetic resonance imaging (MRIs), or whose intracranial tumor burden was prohibitive to SRS. Patient baseline characteristics for the entire cohort are available in Table 1 , with comparative values to the original ds-GPA study 8 in Table 2 .
Radiosurgery Technique
Radiosurgical planning and technique was similar for all patients. MRI studies of the brain were performed using a GE Healthcare MRI machine (Milwaukee, Wisconsin), which generated thin-slice (1 mm) axial and coronal T1-weighted pre-and postcontrast MR sequences. Treatment plans were then generated by a comprehensive radiosurgery team consisting of a radiation oncologist, a neurosurgeon, and a medical physicist. Dosimetric planning was performed with the assistance of Leksell GammaPlan software (Elekta AB, Stockholm, Sweden); additional parameters, including total number of metastases, tumor volume, and a history of prior or planned whole-brain radiotherapy, were taken into account during dosimetric planning. In each case, the prescription dose was delivered to the 50% isodose line. In general, dose assignments across both cohorts were consistent with prescriptions as described in the Radiation Therapy Oncology Group 95-08 clinical trial. 17 Dose to the optic nerve was limited to 10 Gy, while dose to the brainstem was limited to 18 Gy. Single dose to the brain was limited to <4 Gy in most instances. 
Data Collection and Statistical Analysis
For all patients, in-house electronic medical record data were gathered, including patient age, KPS, number of BMs, CITV, and survival time.
Blinding of the predictors and outcomes was unnecessary due to the retrospective nature of data collection in this study. Survival time was defined as the time from SRS to time of death. CITV was defined, as previously published by Marcus et al, 11 as the sum volume of all intracranial metastatic lesions. This sum volume was calculated using Elekta's Gamma Plan software on a pre-SRS T1-weighted postcontrast image.
The ds-GPA model for melanoma serves to grade a patient's mortality risk with a point-based system. In order to validate the inclusion of CITV into the ds-GPA model, we set out to identify CITV as an independent predictor of survival in melanoma BM patients. To do so, we first performed a series of univariate and Pearson's correlation analyses, setting each of the ds-GPA parameters against the measure of CITV to determine the extent of independent association between CITV and each parameter of the ds-GPA (KPS, number of metastases, and overall survival). Whole case analysis was performed for all analyses, with no imputation performed for missing values (see Table 1 ). We next performed a multivariate Cox proportional hazards analysis, in which we set CITV as our main predictor against the continuous outcome of patient death (with time to death measured in months), controlling for the remaining factors within the ds-GPA (KPS and number of metastases), with the aim of determining whether CITV retained prognostic significance for survival after controlling for factors within the ds-GPA. We then subsequently compared the Akaike information criterion (AIC) of each of the models in order to quantify goodness of fit.
Finally, in order to quantify the prognostic benefit of adding CITV to the melanoma ds-GPA, we calculated the improvement in prognostic capability of the ds-GPA model after the incorporation of CITV as a factor (termed ds-GPA-CITV). This improvement was calculated using established statistical measures, including the net reclassification index (NRI > 0) and integrated discrimination improvement (IDI). These 2 measures, NRI and IDI, allow for quantification of the number of correctly reassigned cases (ie, false negative to true negative, false positive to true positive) after implementing a change in a prognostic model (in this case, the addition of CITV to the ds-GPA model). 18 The ds-GPA scale used for this comparison was included as originally proposed 8 and consisted of patient KPS and number of BMs (see Table 3 ). With the addition of a new variable, we opted to increase the maximum possible point score of the ds-GPA-CITV scale to 6 rather than introduce fractional point values into the model. To create the ds-GPA-CITV scale, we used cutoffs for CITV of <4 cc and >4 cc, as previously reported by Marcus et al 11 (see Table 3 ). For the purposes of our multivariate analysis, each factor (CITV, KPS, and number of metastases) was defined according to its points scale in the ds-GPA-CITV model outlined in Table 3 .
All statistical analyses were performed using R version 3.2.3 (The R Foundation for Statistical Computing, Vienna, Austria) and the predictable package for NRI and IDI calculations. P < .05 was considered statistically significant; all tests were 2-sided. AIC from the stats package was used to assess model goodness of fit. Following established practice, a decrease of 2 or more in AIC was deemed to be a clinically important increase in goodness of fit. The package survival was used to create Kaplan-Meier plots. P < .05 was considered statistically significant; all tests were 2-sided.
RESULTS
Patient Demographics, Dosimetry, and Tumor Characteristics
After collecting all available melanoma patients, demographics of the data set were characterized. Pertinent patient demographic and tumor characteristics are shown in Table 1 . The median age of our melanoma cohort was 56.1 yr (range 17-92), and 66.3% of our study population was male. The median KPS was 80 (range 30-100). The median overall survival was 4 mo (range 0-85 mo), and approximately 17% of the study population survived beyond 1 yr. Finally, the median number of metastases was 2 (range 1-40), and the median CITV was 2.5 cc (range 0.01-53.5 cc). The overall characteristics of the study population are comparable to previous studies of melanoma treated with SRS (see Table 2 ). 19, 20 Correlation between CITV and KPS, Number of Metastases, and Overall Survival
As shown in Table 4 , KPS was inversely correlated with CITV (P < .001), such that an increase in CITV was associated with a decrease in patient KPS (Figure 1 ). The number of metastases correlated with CITV (P < .001, Figure 2 ). An increase in the number of metastases was associated with an increase in patient CITV. The number of metastases is also inversely associated with KPS, such that an increased number of metastases is associated with decreased KPS (P < .001, Figure 3) . Finally, patient survival was found to be directly correlated with CITV (P < .001, Figure 4) ; however, when survival was compared against KPS and number of metastases alone, the univariable Pearson's correlation coefficients were determined to be not significant. In Table 5 , further quantification of the relationships between CITV and the aforementioned covariates is shown in the context of univariate linear models. As seen in the table, the direction of the relationships seen in the Pearson's analysis remains true, with KPS and survival in months being inversely correlated with CITV, and number of metastases being directly correlated with CITV.
Association Between CITV and Overall Survival
When CITV was examined in a univariate Cox proportional hazard model in the absence of melanoma ds-GPA variables (Table 6 ), CITV was found to be significantly associated with patient survival. Increasing CITV point score (ie, decreasing measured CITV) was associated with a reduced hazard ratio of patient death (HR = 0.771, P < .001). When examined in the context of a multivariate model with other melanoma ds-GPA- CITV variables, CITV was found to retain its prognostic significance for patient survival after controlling for KPS and number of metastases (P = .008).
To compare the traditional ds-GPA model with the ds-GPA-CITV model, the AIC was calculated for both of the models. The AIC for the ds-GPA model in the context of the study data was found to be 2347, and the AIC for the model with CITV added was found to be 2340, suggesting superiority of the melanoma ds-GPA-CITV model.
Incorporation of CITV Improves the Prognostic Value of Melanoma-Specific GPA
To allow quantitative comparison between melanoma-specific ds-GPA with and without the incorporation of CITV, the values assigned to covariates in the CITV-modified melanoma-specific GPA model (ds-GPA-CITV) were adjusted as shown in Table 3 (as done for our multivariate analysis). The prognostic value of the melanoma-specific GPA and CITV-modified melanoma ds-GPA were compared using 2 statistical measures that are well described in the literature: the continuous NRI> 0 and the IDI. 18 As shown in Table 7 , incorporation of CITV into the ds-GPA resulted in an NRI> 0 of 0.3662 (95% CI: 0.1253-0.6072, P = .0029) and IDI of 0.0238 (95% CI: 0.0077-0.0398, P = .0037), suggesting a significant improvement in the prognostic value of the ds-GPA upon inclusion of CITV as a covariate. We tested whether these findings were robust in an independent cohort of 201 consecutive SRS-treated melanoma BM patients (contributed by GS and VC). The demographic of this cohort is as shown in Table 8 . When CITV was examined in a univariate Cox proportional hazard model in this cohort in the absence of melanoma ds-GPA variables (Table 9) , CITV was found to be significantly associated with patient survival. Increasing CITV point score was associated with a reduced hazard ratio of patient death (HR = 0.750, P < .001). When examined in the context of a multivariate model with other melanoma ds-GPA-CITV variables, CITV was found to retain its prognostic significance for patient survival in this validation cohort after controlling for KPS and number of metastases (HR = 0.799, P = .003).
To compare the traditional ds-GPA model with the ds-GPA-CITV model in this validation cohort, the AIC was calculated for both of the models. The AIC for the ds-GPA model in the context of the study data was found to be 1722, and the AIC for the model with CITV added was found to be 1716, suggesting that CITV improves the prognostic value of melanoma ds-GPA. Further supporting this finding, incorporation of CITV into the ds-GPA model for melanoma resulted in an NRI of 0.485 with an associated P = .002.
DISCUSSION
Arguably, melanoma is one of the most radio-resistant forms of BM. 21, 22 Treatment failure is observed in >25% of melanoma BM after treatment with SRS. 23 This failure rate compares poorly to those reported for lung BM, in which <10% of treated lesions fail SRS. 24, 25 We previously reported the prognostic value of CITV in lung cancer patients when incorporated into the lungspecific ds-GPA scale (which included age, KPS, number of metastases, primary tumor histology, and the extracranial metastasis). 11 Here, we demonstrated that CITV plays a similarly important role for survival prognostication in melanoma BM patients. Moreover, our results indicate that incorporating CITV into the ds-GPA model for melanoma significantly improves the Table 3 (CITV > 4 cc = 0 points, CITV ≤ 4 cc = 2 points). b CITV = cumulative intracranial tumor volume; ds-GPA = disease-specific graded prognostic assessment; KPS = Karnofsky performance status. prognostic capacity of the model, in line with previous work demonstrating the prognostic utility of CITV. 26 Using our previously established cutoff of 4 cc for CITV point assignments, 11 we demonstrated a significant prognostic effect of CITV for overall survival, even after controlling for the remaining ds-GPA variables of KPS and number of metastases. Upon Cox proportional hazard model analysis, we demonstrated that not only does CITV retain significance when added to the ds-GPA model, but it also augments the goodness of fit of the model as measured by AIC. More impressively, it does so despite the fact that the ds-GPA-CITV model is a 3-term model vs the original 2-term ds-GPA model. This is striking, as AIC penalizes the inclusion of additional terms in order to prevent the overfitting of data to a particular model.
We then wished to further compare the ds-GPA model to the ds-GPA model with CITV. After comparing models by established statistical measures (NRI > 0 and IDI), the modified model of melanoma ds-GPA that incorporates CITV conferred improved survival prognostication relative to the published ds-GPA. The magnitude of this improvement (NRI = 0.366 and IDI = 0.024) is on par with that reported for high-density lipoprotein for 10-yr cardiac risk estimation. 27 A central issue that requires resolution in future studies of CITV involves the determination of whether death was caused by progression of the intracranial disease or systemic disease. The former scenario would suggest that CITV works as a proxy for insufficient dose delivery (due to dose constraint related to a larger volume) or inherent radiation resistance of the intracranial lesion. In either case, the patient may benefit from surgical resection in this former scenario. The latter scenario suggests CITV serves as a proxy for the severity of systemic disease. In this case, the patients may benefit from more intensive therapeutic regimens. The cause Table 3 (CITV > 4 cc = 0 points, CITV ≤ 4 cc = 2 points).
of death in cancer patients is not a trivial determination; 28, 29 therefore, careful study design will be required in future studies aimed to address this matter.
As a retrospective study of SRS-treated melanoma patients, our conclusions should be interpreted with caution given the various biases inherent in this study design. Accordingly, our results can be strengthened through confirmation in an independent cohort. As survival expectations in melanoma patients are increasingly modified by the use of molecularly targeted agents as well as immunotherapy, efforts should be made to incorporate these variables in future studies and understand how these agents affected survival prediction by melanoma disease-specific GPA and CITV.
CONCLUSION
CITV is an important prognostic variable for melanoma patients suffering from BM and augments survival prognostication when incorporated into melanoma ds-GPA.
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